Drug intelligence / Profile preview

SB2

Development stage: Phase 3
Lead developer: Samsung Bioepis
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

SB2 is a biosimilar of infliximab, a chimeric human-murine immunoglobulin G1 (IgG1) monoclonal antibody that binds to human tumor necrosis factor alpha (TNF-α). It is approved for the treatment of immune-mediated inflammatory diseases including rheumatoid arthritis, ankylosing spondylitis, adult and pediatric Crohn's disease, adult and pediatric ulcerative colitis, psoriatic arthritis, and plaque psoriasis. SB2 was developed by Samsung Bioepis and has been shown to be similar to reference infliximab in terms of physicochemical attributes, TNF-α binding, TNF-α neutralization activities, and Fc-related biological activities.

Brand names: FlixabiRenflexis
Other names: infliximab-abda

Targets

TNFA (Tumor necrosis factor alpha (soluble))

Beyond the preview

Go deeper on SB2.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SB2.

Explore the full profile